131 related articles for article (PubMed ID: 31532265)
1. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study.
Af Björkesten CG; Jussila A; Kemppainen H; Hallinen T; Soini E; Mankinen P; Valgarðsson S; Veckman V; Nissinen R; Naessens D; Molander P
Scand J Gastroenterol; 2019 Oct; 54(10):1226-1232. PubMed ID: 31532265
[No Abstract] [Full Text] [Related]
2. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.
Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
J Crohns Colitis; 2014 Sep; 8(9):1022-9. PubMed ID: 24566170
[TBL] [Abstract][Full Text] [Related]
3. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
4. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up.
Jones GR; Fascì-Spurio F; Kennedy NA; Plevris N; Jenkinson P; Lyons M; Wong L; MacLean P; Glancy S; Lees CW
J Crohns Colitis; 2019 Mar; 13(4):442-450. PubMed ID: 30452618
[TBL] [Abstract][Full Text] [Related]
5. Elevated Faecal Calprotectin Levels are a Reliable Non-Invasive Screening Tool for Small Bowel Crohn's Disease in Patients Undergoing Capsule Endoscopy.
Yousuf H; Aleem U; Egan R; Maheshwari P; Mohamad J; McNamara D
Dig Dis; 2018; 36(3):202-208. PubMed ID: 29466790
[TBL] [Abstract][Full Text] [Related]
6. Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's Disease.
Veyre F; Boschetti G; Meunier C; Cuerq C; Gay C; Charlois AL; Duclaux-Loras R; Danion P; Cotte E; Kepenekian V; Mialon A; Faure M; Roblin X; Flourie B; Nancey S
Dig Dis Sci; 2021 Dec; 66(12):4429-4435. PubMed ID: 33387123
[TBL] [Abstract][Full Text] [Related]
7. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.
Papamichael K; Karatzas P; Mantzaris GJ
J Crohns Colitis; 2016 Mar; 10(3):371-2. PubMed ID: 26546496
[No Abstract] [Full Text] [Related]
8. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis.
Bathe AL; Mavropoulou E; Mechie NC; Petzold G; Ellenrieder V; Kunsch S; Amanzada A
PLoS One; 2019; 14(10):e0223893. PubMed ID: 31647834
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
10. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
11. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases.
Molander P; Kemppainen H; Ilus T; Sipponen T
Scand J Gastroenterol; 2020 Jan; 55(1):34-40. PubMed ID: 31841064
[No Abstract] [Full Text] [Related]
12. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
13. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease.
Verdejo C; Hervías D; Roncero Ó; Arias Á; Bouhmidi A; Lorente R; Salueña I; Lucendo AJ
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1521-1527. PubMed ID: 30303822
[TBL] [Abstract][Full Text] [Related]
15. A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.
Cerrillo E; Moret I; Iborra M; Pamies J; Hervás D; Tortosa L; Sáez-González E; Nos P; Beltrán B
Inflamm Bowel Dis; 2019 Sep; 25(10):1681-1691. PubMed ID: 30925193
[TBL] [Abstract][Full Text] [Related]
16. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
[TBL] [Abstract][Full Text] [Related]
17. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement.
Esatoglu SN; Hatemi I; Ozguler Y; Hatemi G; Uzun H; Celik AF; Yazici H
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):90-96. PubMed ID: 30582504
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
